http://flandersbio.be/news/ en info@flandersbio.be Copyright 2012 2012-05-23T14:09:27+00:00 http://flandersbio.be/news/dr-patrik-de-haes-to-be-presented-as-the-new-chairman-of-flandersbio-at-knowledge-for-growth/ Patrik De Haes has been appointed as the new chairman of the Board of Directors of FlandersBio. He succeeds Johan Cardoen who stands down after five years in the post. Patrik De Haes, who is the CEO of ThromboGenics, has been a director of FlandersBio for the last two years. 2012-05-23T14:09:27+00:00 http://flandersbio.be/news/mdxhealths-confirmmdxtm-for-prostate-cancer-test-helps-to-identify-men-/ MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx™ for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy. 2012-05-23T12:10:24+00:00 http://flandersbio.be/news/cryo-save-group-nv-appointment-of-ms-karin-dorrepaal-as-non-executive-director-/ Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, is happy to welcome Ms. Karin Dorrepaal, PhD, MBA as its new Non-Executive Director. 2012-05-22T06:33:00+00:00 http://flandersbio.be/news/biomarker-predicts-response-to-cancer-treatment-/ VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery could be an important step towards personalized medicine and patient-tailored use of this important cancer drug. 2012-05-21T11:45:40+00:00 http://flandersbio.be/news/niet-india-maar-pfizer-puurs-haalt-investering/ 2012-05-18T14:20:14+00:00 http://flandersbio.be/news/cardio3-biosciences-has-been-selected-to-present-c3bs-cqr-1-trial-data-/ The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22. 2012-05-18T09:28:04+00:00 http://flandersbio.be/news/galapagos-nv-business-update-/ Galapagos NV (Euronext: GLPG) announces today that the operational and financial results achieved thus far in 2012 encourage the Company to retain full year 2012 financial guidance given earlier this year: Group revenues of over €150 million (+30%), increased cash and profit contribution from the service operations, with positive Group operational income and cash flow, and a positive Group net result in 2012. 2012-05-18T07:24:40+00:00 http://flandersbio.be/news/ablynx-announces-q1-2012-business-update/ Ablynx [Euronext Brussels: ABLX], the Belgian-based biopharmaceutical company focused on the discovery and development of Nanobodies® for the treatment of serious life-threatening diseases, today announced its business update for the three-month period ending 31st March 2012. 2012-05-17T06:51:57+00:00 http://flandersbio.be/news/christine-van-broeckhoven-given-prestigious-metlife-award-for-medical-research-worth-250000/ On Tuesday, May 15, in New York, the MetLife Foundation handed its annual Award for Medical Research to Christine Van Broeckhoven, of VIB and Universiteit Antwerpen, for her pioneering research on Alzheimer's disease and related disorders. This prestigious scientific award is given to outstanding scientific researchers. The substantial amount attached to the award is meant to give researchers the chance and free rein to develop new research ideas in the fight against dementia. 2012-05-16T11:18:13+00:00 http://flandersbio.be/news/durfkapitaalpoot-kbc-keert-overtollige-cash-uit-aan-moederbedrijf/ 2012-05-16T11:17:06+00:00